Clinical Trial Update: PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood [Phase 2]

View source ↗

Summary

Phase II open-label pilot trial evaluating everolimus (Certican) for the prevention of chronic graft-versus-host disease and late pulmonary complications after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Certican (everolimus)

Snippet

Sponsor: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Conditions: Condition After Allogenic Peripheral Stem Cell Transplantation (SCT) | Phase 2 | Status: COMPLETED